Efficacy and Safety of a New 5% Minoxidil Formulation in Male Androgenetic Alopecia: A Randomized, Placebo-Controlled, Double-Blind, Noninferiority Study

The study evaluated the efficacy and safety of a new 5% minoxidil formulation, DC0120, in stimulating hair growth in men with androgenetic alopecia (AGA). The study was a randomized, double-blind, placebo-controlled trial involving 220-231 subjects. The results showed that DC0120 was noninferior to a marketed comparator (ALOSTIL®) in increasing nonvellus target area hair count (TAHC) and cumulative hair thickness density. The treatment-related adverse events were mild or moderate, and none could be attributed specifically to DC0120 or the comparator product. The study concluded that DC0120 is a safe and effective treatment for AGA in men.